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Include Disvussion
Acquired or innate resistance to chemotherapy poses a
significant challenge in the treatment of head and neck
squamous cell carcinoma (HNSCC) resulting in relapse,
metastasis and increased mortality. 
Chemotherapy resistance occurs when small populations of
cancer cells evade the cytotoxicity of cancer drugs and are
able to survive and propagate.
HNSCCs are often treated with a combination of surgery,
radiation and chemotherapy, with cisplatin being a
standard-of-care chemotherapy drug.
Human papillomavirus (HPV) is detected in about 25% of all
HNSCCs. 
HPV-associated HNSCCs have distinct molecular
mechanisms underlying the cancer progression, when
compared to HPV-negative HNSCCs (Kreimer, 2005).          
HPV-positive HNSCC are also known to have significantly
better prognosis in response to treatment when compared to
HPV-negative HNSCCs (Fakhry, 2008).
However, about 15-20% of HPV+ HNSCC patients fail to




Adapted from “Intrinsic and Acquired Drug Resistance, by BioRender.com
(2021). Retrieved from https://app.biorender.com/biorender-templates  
METHODS
Translational Head and Neck Cancer Lab, Schulich School of Medicine & Dentistry, 
Western University, London, ON, Canada
 
Generating Cisplatin Resistant HPV-positive HNSCC cell lines 




The molecular and genetic basis of cisplatin resistance in HPV-
positive HNSCC is not well-defined.
RATIONALE
The purpose of this experiment is to generate in-vitro models of
cisplatin resistance in five HPV+ HNSCC cell lines for further
studies.
OBJECTIVE Much thanks to Dr. Anthony Nichols, Dr. Mushfiq
Shaikh, Dr. John Barrett, Alana Sorgini and all other
researchers and employees of the Translational Head
and Neck Cancer Lab.
FUTURE STEPS
Once the cisplatin resistant cell lines have been
generated and expanded, the IC50 values will be
calculated again to validate the increased resistance to
cisplatin.
Additionally, the genetic profile of the resistant cells will
be explored by sequencing, analysis, and comparison
with genome-wide CRISPR knockout screening data.
We aim to characterize the genes that may underlie
the molecular and genetic basis of cisplatin
resistance in HPV+ HNSCC.
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PRELIMINARY RESULTS






The result indicates UMSCC47 cells are most resistant to
cisplatin while UPCI:SCC90 cells are the most sensitive. 
The concentration of cisplatin required to kill 50% of cells (IC50) was
determined for each of the five HPV+ HNSCC lines.
Cell lines: UWO23, UWO37, UMSCC47, UPCI:SCC90, 93VU147T
500,000 of each of the cell lines were plated in three flasks and treated 2x,
5x, and 10x their cisplatin IC50 concentrations respectively. 
The cells were administered cisplatin every 4 days and were frequently
observed using a light microscope. 
Once single cell colonies of cisplatin-resistant cells are formed, they will be
isolated and expanded.
Cisplatin resistant cell lines will be used in future experiments.
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TREATMENT CONDITIONS
DETERMINING THE IC50 VALUES
CONCLUSION
The generation of the cisplatin resistant cell lines will
allow us to explore the underlying mechanism of
cisplatin resistance in HPV+ cell lines.
Clinically, it will potentially improve the treatment
regimen of patients with treatment resistant diseases.
 
